XKEM aktuel empfohlen unter:

Bhuwan Pandey, Vice President Operations for Xechem International, who had served as acting General Manager of Xechem Nigeria in Abuja since its inception in 2002 and who shepherded the NICOSAN(TM) project to the current stage of development, said "I am truly honored to have played a part in bringing this revolutionary non-toxic Sickle Cell Disease drug to the market. I welcome Mr. Oniyide with open arms and officially turn over to him the day-to-day management of Xechem Nigeria on this auspicious day. I have no doubt that under his leadership and guidance, the company will continue to grow and prosper."

Dr. Ramesh Pandey, Chairman of Xechem International and Xechem Pharmaceutical Nigeria also welcomed Mr. Oniyide's ascension as Managing Director for Xechem Nigeria. According to Dr. Pandey, "I am sure that as our new Managing Director, Mr. Oniyide will help take Xechem Nigeria to greater heights and make all of Nigeria proud. I look forward to working closely with him on the historic work we are doing in Nigeria."

Reflecting on the achievements already made by Xechem Nigeria to date, Dr. Pandey stated, "We owe a large measure of gratitude to a great many people to have arrived at this stage. I would like to thank Bhuwan Pandey and his team for their contribution, dedication and tireless efforts in overcoming the many challenges and obstacles they have faced in bringing the NICOSAN(TM) drug to the Nigerian market."

"I am also very grateful to, and would like to acknowledge, some of the people and organizations that have been instrumental in Xechem Nigeria's development, starting with the President of the Federal Republic of Nigeria, Chief Olusegun Obasanjo, GCFR, who officially launched NICOSAN(TM) on July 6, 2006 from the facility at the company's SHESTCO complex." Dr. Pandey continued, "Working together with the Honorable Minister of Science and Technology, Professor Turner Isoun and the Honorable Minister of Health, Professor Eyitayo Lambo, the dream of bringing NICOSAN(TM) to the SCD afflicted population has become a reality. Also deserving of our gratitude is Dr. Ayo Coker, Director General of SHESTCO. Without his full support and guidance, we would not be in production today. I also extend my thanks to Dr. Uford Inyang, Director General at the National Institute for Pharmaceutical Research and Development (NIPRD), which first brought NICOSAN(TM) to the attention of Xechem following years of development and testing at NIPRD."

Dr. Pandey went on to say "our thanks must also go out to Professor Soji Adelaja and Stephen Burg, board members of both Xechem International and Xechem Nigeria, for their role in the company's success to date. There are many others, including Xechem Nigeria board members Lady Ekaette and Isaac Inyang, who have given selflessly of their time to help us achieve this success. Finally, the dedicated people who work at the facility must also be recognized for their individual efforts in helping to bring this drug to the people of Nigeria and the World."

About NICOSAN(TM)

NICOSAN(TM) is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN(TM).

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.

Source: Xechem International, Inc.

Ein Phase IIb Versuch von Nicosan wurde an einem Armeunterseite Krankenhaus in Yaba, Lagos, Nigeria zwischen 1996 und 1997 geleitet. Xechem berichtet über dem „73% der 30 Patienten, die an der Studie erfuhren keine Krise während der 12 Monat Probeperiode teilnahmen und das restliche 27% die weniger häufigen und weniger strengen Krisen erfuhr. “ [1]

Hauptresultate

Reports von zwei Versuchen wurden gefunden, von denen nur eins, einschließlich 82 Teilnehmer, für Einbeziehung in diesem Bericht geeignet war. Dieser Phase IIB (Angel) Versuch schlägt vor, daß ein phytomedicine, Nicosan®, wirkungsvoll war, wenn es die Episoden der SCD Krise verbunden mit den strengen Schmerz über einen Sechsmonatszeitraum verringerte. Nicosan® schien nicht, die Gefahr der strengen Komplikationen oder das Niveau der Anämie zu beeinflussen. Keine ernsten schädlichen Wirkungen wurden berichtet.

Zusammenfassungen der Autoren

Während Nicosan®, wie phytomedicine, schien, sicher und wirkungsvoll zu sein, wenn er die Krisen verringerte, die mit den strengen Schmerz über einen Sechsmonatsanschlußzeitraum dieses Versuches verbunden sind, werden weitere Versuche angefordert, um seine Rolle im Management der Leute mit Sichelzelle Krankheit festzusetzen. Die Resultate Phase III, multicentre Versuche werden erwartet. www.cochrane.org/reviews/en/ab004448.html


Das hergestellte Droge hydroxyurea dient in SCD als ein antisickling Mittel, gleichwohl nicht alle Patienten auf diese Droge reagieren und einige schädliche Wirkungen erfahren, einschließlich Myelosuppression. Nicosan mit vielleicht weniger schädlichen Wirkungen scheint auch, durch „einen starken antisickling Effekt“ zu arbeiten. [2]

[redigieren], Fußnoten

  1. ^ Xechem international - jährlicher Bericht (31. Dezember 2005). Zurückgeholt auf 2006-07-21. - Unterordnung USsicherheiten und Austausch-zur Kommission
  2. ^ Iyamu E, Turner E, Asakura T (2002). „In-vitroeffekte von NIPRISAN (Nix-0699): ein natürlich vorkommendes, starkes antisickling Mittel.“. Br J Haematol 118 (1): 337-43. PMID 12100171.

[redigieren], externe Verbindungen